Key Points
- Michael Skaff, a major shareholder, purchased 1,353,625 shares of Vivos Therapeutics on March 31 at an average price of $1.34 per share, totaling about $1.81 million, per an SEC filing.
- Vivos trades around $1.32 with a 12‑month range of $1.09–$7.95 and a market cap near $13.8M; the company shows negative earnings (PE -0.75), high leverage (debt/equity 3.31) and a volatile beta (6.93), signaling elevated risk.
- Analyst sentiment is mixed — consensus is Hold with an average price target of $4.92 (2 Buy / 2 Hold / 1 Sell) while Weiss Ratings reaffirmed a sell (e+); institutional ownership is about 26.35% with several recent position changes.
Vivos Therapeutics, Inc. (NASDAQ:VVOS - Get Free Report) major shareholder Michael Skaff purchased 1,353,625 shares of Vivos Therapeutics stock in a transaction dated Tuesday, March 31st. The stock was bought at an average price of $1.34 per share, for a total transaction of $1,813,857.50. Following the completion of the transaction, the insider directly owned 1,353,625 shares in the company, valued at $1,813,857.50. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Vivos Therapeutics Trading Up 1.5%
NASDAQ VVOS opened at $1.32 on Friday. Vivos Therapeutics, Inc. has a 12 month low of $1.09 and a 12 month high of $7.95. The stock has a 50-day simple moving average of $1.44 and a 200 day simple moving average of $2.14. The company has a current ratio of 0.78, a quick ratio of 0.78 and a debt-to-equity ratio of 3.31. The company has a market capitalization of $13.82 million, a PE ratio of -0.75 and a beta of 6.93.
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Vivos Therapeutics in a research note on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Vivos Therapeutics currently has a consensus rating of "Hold" and an average price target of $4.92.
Get Our Latest Report on Vivos Therapeutics
Institutional Investors Weigh In On Vivos Therapeutics
Several large investors have recently modified their holdings of VVOS. Connective Capital Management LLC bought a new stake in shares of Vivos Therapeutics in the third quarter worth about $620,000. DRW Securities LLC grew its position in shares of Vivos Therapeutics by 179.5% in the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company's stock valued at $235,000 after purchasing an additional 74,441 shares during the period. B. Riley Wealth Advisors Inc. acquired a new position in shares of Vivos Therapeutics in the 2nd quarter valued at approximately $220,000. XTX Topco Ltd bought a new stake in Vivos Therapeutics during the 2nd quarter worth approximately $65,000. Finally, Acorn Wealth Advisors LLC acquired a new stake in Vivos Therapeutics during the 4th quarter worth approximately $30,000. 26.35% of the stock is currently owned by institutional investors.
About Vivos Therapeutics
(
Get Free Report)
Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company's proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.
The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
